Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Stock Price Down 31.3%
Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB)’s share price dropped 31.3% on Friday . The stock traded as low as $0.68 and last traded at $0.68. Approximately 3,318,500 shares changed hands during mid-day trading, an increase of 4,192% from the average daily volume of 77,313 shares. The stock had previously closed at $0.99.
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter. The company had revenue of $0.14 million during the quarter.
In other Navidea Biopharmaceuticals news, major shareholder John K. Jr. Scott purchased 357,143 shares of the business’s stock in a transaction that occurred on Friday, March 22nd. The stock was purchased at an average price of $0.14 per share, for a total transaction of $50,000.02. Following the purchase, the insider now directly owns 22,261,565 shares in the company, valued at $3,116,619.10. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last 90 days, insiders purchased 368,443 shares of company stock valued at $68,490.
WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/navidea-biopharmaceuticals-nyseamericannavb-stock-price-down-31-3/3043243.html.
About Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.
See Also: Bull Market
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.